GW Pharmaceuticals PLC (GWPH)
84.52
-0.48 -0.56%
NASDAQ
Apr 2, 20:00
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 311.33M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -0.48 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -9.019M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 93.31% |
| Profit Margin (Quarterly) | -22.87% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 2.618B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 8.438 |
| PE Ratio | -- |
| Price to Book Value | 3.606 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | -27.34M |
| Return on Equity | Upgrade |
View All GWPH News
News
-
WireHeadlineTime (ET)
-
MT Newswires03/31 08:04
-
SA Breaking News03/31 07:49
-
Globe Newswire03/31 07:00
-
Yahoo03/24 16:20
-
Yahoo03/20 07:05
-
MT Newswires03/19 07:38
-
MT Newswires03/13 13:10
-
SA Breaking News03/13 08:22
-
SA Breaking News03/13 07:28
-
Globe Newswire03/13 07:00
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 05/06/2020 16:30 EDT | Misc | GW Pharmaceuticals PLC First Quarter Earnings Conference Call in 2020 |
| 05/06/2020 | Earnings | GW Pharmaceuticals PLC First Quarter Earnings in 2020 Release |
| 02/27/2020 | Misc | GW Pharmaceuticals PLC Annual Report for 2019 |
| 02/25/2020 16:30 EST | Misc | GW Pharmaceuticals PLC Fourth Quarter Earnings Conference Call for 2019 |
| 02/25/2020 | Earnings | GW Pharmaceuticals PLC Fourth Quarter Earnings in 2019 Release |
| 11/05/2019 16:30 EST | Misc | GW Pharmaceuticals PLC Third Quarter Earnings Conference Call for 2019 |
| 11/05/2019 | Earnings | GW Pharmaceuticals PLC Third Quarter Earnings in 2019 Release |
| 08/06/2019 16:30 EDT | Misc | GW Pharmaceuticals PLC Second Quarter Earnings Conference Call in 2019 |
| 08/06/2019 | Earnings | GW Pharmaceuticals PLC Second Quarter Earnings in 2019 Release |
| 06/13/2019 10:00 BST | Misc | GW Pharmaceuticals PLC Annual General Meeting in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.gwpharm.com
- Investor Relations URL: http://ir.gwpharm.com/
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Equity Style: Mid Cap/Value
- Next Earnings Release: May. 06, 2020
- Last Earnings Release: Feb. 25, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 84.52 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| HMMJ.TO | Horizons Marijuana Life Sciences ETF | 11.42% |
| MJ | ETFMG Alternative Harvest ETF | 8.61% |
| YOLO | AdvisorShares Pure Cannabis ETF | 7.10% |
| FRBRX | Franklin Biotechnology Discovery R6 | 3.47% |
| BCSVX | Brown Capital Mgmt Intl Sm Co Inv | 2.32% |
| AHSCX | Alger Health Sciences C | 2.29% |
| GLO | Clough Global Opportunities | 1.96% |
| GLQ | Clough Global Equity | 1.91% |
| ETCHX | Eventide Healthcare & Life Sciences C | 1.86% |
| PPH | VanEck Vectors Pharmaceutical ETF | 1.37% |
| FSSRX | Franklin Small Cap Growth R | 1.19% |
| WSCAX | Wanger International | 1.06% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- GWPH Tweets Stocktwits
Advertisement
